Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

AJMC
Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

The Evolution of CLL Testing and Treatment Over the Past Decade
October 30th 2018

The Evolution of CLL Testing and Treatment Over the Past Decade

Laura Joszt, MA
In the last decade, testing for and treatment of chronic lymphocytic leukemia (CLL) had undergone substantial changes with new testing that can personalize therapy and new agents that provide more clinical benefit.
Site Logo
October 30th 2018

COA's OCM 2.0: Moving Toward a Universal Payment Model

Surabhi Dangi-Garimella, PhD
The Community Oncology Alliance (COA) has been working with its member practices and some payer partners who have successfully implemented innovative care delivery and payment models to develop a 2.0 version of CMS’ Oncology Care Model (OCM). A progress report was presented at COA’s Payer Exchange Summit held October 29-30 in Tyson’s Corner, Virginia.
Site Logo
October 30th 2018

Community Practices Continue to Struggle With ED Use, Risk Stratification in OCM

Surabhi Dangi-Garimella, PhD
While practice transformation is vital, community-based clinics continue to struggle with emergency department (ED) use, hospitalization, and risk stratification as they identify ways to reduce unnecessary expenditures within their Oncology Care Model (OCM) practice.
Implications of OCM Reports and the Future of the Program
October 29th 2018

Implications of OCM Reports and the Future of the Program

Laura Joszt, MA
Lalan Wilfong, MD, moderated a conversation between Robert E. Baird, MD, CEO of Dayton Physicians Network, and Sarah Cevallos, chief revenue cycle officer for Florida Cancer Specialists and Research Institute, about current and future strategies for Oncology Care Model (OCM) participation, as well as key lessons from the OCM and how they can be applied in other reform models.
Podcast: This Week in Managed Care—States Gain Power to Alter ACA Offerings and Other Health News
October 27th 2018

Podcast: This Week in Managed Care—States Gain Power to Alter ACA Offerings and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This Week in Managed Care: October 26, 2018
October 26th 2018

This Week in Managed Care: October 26, 2018

This week, the top managed care news included the Trump administration giving governors the power to overhaul section 1332 waivers under the Affordable Care Act (ACA); CMS disclosed a breach in the portal that agents and brokers use to assist consumers signing up for health coverage under the ACA; about one-third of all US healthcare payments in 2017 were tied to alternative payment models.
Palbociclib Plus Fulvestrant Increases OS in HR+, HER2-Negative Breast Cancer
October 26th 2018

Palbociclib Plus Fulvestrant Increases OS in HR+, HER2-Negative Breast Cancer

Samantha DiGrande
A recent trial sought to assess the effect of palbociclib on overall survival (OS) and the efficacy of subsequent therapy in patients with hormone receptor–positive (HR+), HER2-negative advanced breast cancer.
Immunotherapy Is Safe for Patients With Cancer Living With HIV
October 25th 2018

Immunotherapy Is Safe for Patients With Cancer Living With HIV

Jaime Rosenberg
According to a study presented at the ESMO 2018 Congress in Munich, Germany, treatment with PD-1 or PD-L1 inhibitors is a feasible option for patients who have cancer and are living with HIV.
Looking Back at CAR T: PROs From a Patient's Perspective
October 23rd 2018

Looking Back at CAR T: PROs From a Patient's Perspective

A survivor of chronic lymphocytic leukemia who participated in the first chimeric antigen receptor T-cell trial in 2010 looks back at his experience and also discusses his views on how patient-reported outcomes (PROs) should be used, if at all, by CMS.
Atezolizumab Plus Chemotherapy Prolongs PFS in Triple-Negative Breast Cancer
October 23rd 2018

Atezolizumab Plus Chemotherapy Prolongs PFS in Triple-Negative Breast Cancer

Samantha DiGrande
A phase 3 trial recently investigated if nanoparticle albumin-bound paclitaxel enhances the treatment of atezolizumab in unresectable locally advanced or metastatic triple-negative breast cancer.
Dr Thorvardur Halfdanarson on if He Thinks There's a Future For Immunotherapy in NETs
October 23rd 2018

Dr Thorvardur Halfdanarson on if He Thinks There's a Future For Immunotherapy in NETs

It’s fair to say that the initial results of immunotherapy in neuroendocrine tumors (NETs) have been somewhat disappointing, explained Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic.
ACO Engagement With Urologists Can Reduce Overtreatment of Prostate Cancer
October 21st 2018

ACO Engagement With Urologists Can Reduce Overtreatment of Prostate Cancer

Laura Joszt, MA
Accountable care organizations (ACOs) in the Medicare Shared Savings Program vary considerably in how they treat men with newly diagnosed prostate cancer, according to a study that assessed whether the level of engagement in ACOs by urologists could affect rates of treatment, overtreatment, and spending in prostate cancer care.
One Gene Could Be Responsible for Acute Myeloid Leukemia
October 21st 2018

One Gene Could Be Responsible for Acute Myeloid Leukemia

Laura Joszt, MA
The EVI1 gene may be single-handedly at fault for acute myeloid leukemia, according to research published in Nature Communications.
Cancer Care Pathway Utilization Reduces Cost in Breast Cancer
October 20th 2018

Cancer Care Pathway Utilization Reduces Cost in Breast Cancer

Samantha DiGrande
A recent study looked to use real-world data to support the value of pathway regimens designed to create high-quality, affordable treatment in breast cancer care.
Site Logo
October 19th 2018

AJMC®tv Interviews

Laura Joszt, MA Kelly Davio
AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers—from the clinician, to the health plan leader, to the regulator. When every minute in your day matters,AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.
Site Logo
October 19th 2018

From the Editor-In-Chief: Getting to The Prestige in Cancer Care

Joseph Alvarnas, MD
“Every great magic trick consists of three parts or acts. The first part is called ‘The Pledge.’ The magician shows you something ordinary. ...The second act is called ‘The Turn.’ The magician takes the ordinary something and makes it do something extraordinary. Now you’re looking for the secret, but you won’t find it, because of course you’re not really looking...Every magic trick has a third act, the hardest part, the part we call ‘The Prestige.’” — Christopher Priest, The Prestige
Switchable CAR T Cells May Be Safer in Pancreatic Cancer
October 19th 2018

Switchable CAR T Cells May Be Safer in Pancreatic Cancer

David Bai, PharmD
Switchable chimeric antigen receptor (CAR) T cells with a switch directed towards human epidermal growth factor receptor 2 (HER2) in pancreatic ductal adenocarcinoma (PDAC) has similar efficacy as conventional HER2 CAR T cells while also having a greater control over treatment toxicities.
Dr Scott Paulson on Standard of Treatment, Novel Approaches Being Taken in GEP-NETs
October 19th 2018

Dr Scott Paulson on Standard of Treatment, Novel Approaches Being Taken in GEP-NETs

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, explains the current standard of treatment and novel approaches being taken in gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Site Logo
October 18th 2018

EBO October 2018: Clinical Updates

David Bai, PharmD Allison Inserro Laura Joszt, MA Samantha DiGrande Jaime Rosenberg Mary K. Caffrey
Site Logo
October 18th 2018

Managed Care Updates

David Bai, PharmD Allison Inserro Laura Joszt, MA Samantha DiGrande Jaime Rosenberg Mary K. Caffrey
Site Logo
October 18th 2018

The Nobel Prize: Checkpoint Inhibitors

Nobel Prize winner James Allison, PhD, pioneering T-cell researcher, said the award represents the triumph of science and shows the value of research, even if it does not immediately lead to a scientific or commercial success.
What We're Reading: UnitedHealthcare Prefers Biosimilars; Migraine Coverage; Prostate Cancer Disparity
October 18th 2018

What We're Reading: UnitedHealthcare Prefers Biosimilars; Migraine Coverage; Prostate Cancer Disparity

AJMC Staff
UnitedHealthcare has announced it is listing 3 biosimilars as preferred drugs; Express Scripts has decided it will cover Eli Lilly’s and Amgen’s migraine drugs and will not cover Teva Pharmaceutical's drug; black men are more likely to get and die from prostate cancer compared with white men, but they are underrepresented in prostate cancer research because of a general distrust of the healthcare system.
Combination of Bleomycin and G-CSF Does Not Increase Risk for Bleomycin-Induced Pulmonary Toxicity
October 18th 2018

Combination of Bleomycin and G-CSF Does Not Increase Risk for Bleomycin-Induced Pulmonary Toxicity

Jaime Rosenberg
A study has found no evidence that bleomycin plus granulocyte-stimulating factor (G-CSF) increases the risk for bleomycin-induced pulmonary toxicity in patients with Hodgkin lymphoma.
Opdivo Fails to Meet Primary Endpoint in Phase 3 SCLC Trial
October 17th 2018

Opdivo Fails to Meet Primary Endpoint in Phase 3 SCLC Trial

Samantha DiGrande
Last week, Bristol-Myers Squibb announced results from the phase 3 CheckMate -331 trial that investigated nivolumab (Opdivo) versus the current standard of care, chemotherapy, in the treatment of patients with small cell lung cancer (SCLC) who relapsed following platinum-based chemotherapy. The trial found that nivolumab did not significantly increase overall survival compared with chemotherapy.
Dr Heloisa Soares on the Importance of Multidisciplinary Care, Patient Engagement in NETs
October 17th 2018

Dr Heloisa Soares on the Importance of Multidisciplinary Care, Patient Engagement in NETs

Heloisa Soares, MD, assistant professor, University of New Mexico Cancer Center-Albuquerque, discusses the importance of treating neuroendocrine tumors with a multidisciplinary team, as well as the importance of engaging patients and their families in their care.
Site Logo
October 16th 2018

Nurse Practitioners Can Lead the Way in Affecting Colorectal Cancer Screening

A recent survey investigates the role nurse practitioners can play to promote colorectal cancer screening.
Site Logo
October 16th 2018

Squaring Value-Based Payment With Innovation in Oncology

Mary Caffrey
Finding a place for value-based payment with the fast paced innovation in oncology.
Site Logo
October 16th 2018

Medical Marijuana in Cancer Treatment: No Standards of Care, and So Far, No Coverage

Samantha DiGrande
Over the past decade, both recreational and medical marijuana use in the United States has grown tremendously. However, disputes surrounding the legal and ethical implications, safe administration, dispensing, health consequences, and therapeutic indications– albeit based on very limited clinical data– related to its usage abound.
Site Logo
October 15th 2018

Patient Satisfaction Surveys: A Continuous NCODA Initiative for Improvement Within the Oncology Dispensing Practice

Joshua J. Nubla, PharmD Robert D. Orzechowski, MBA Aaron Budge, PharmD
NCODA presents findings from over 700 patient responses across the country to determine patient satisfaction over 4 categories: time, convenience, staff interaction, and overall satisfaction.
Site Logo
October 15th 2018

Survey of NCI-Designated Cancer Centers Finds Most Are Out-of-Network on Exchanges

Alyssa Schatz, MSW Katy Winckworth-Prejsnar, MPH
The National Comprehensive Cancer Network (NCCN) in collaboration with Avalere Health present survey results examining the experiences National Cancer Institute (NCI)-designated cancer centers have had with the marketplaces, the implications for patients' access to cancer care, and proposed policy solutions.
<1
...
363738394041424344
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo